Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens

• Published in: Vaccine Vol. 25; no. 29; pp. 5263 - 5271
• Main Authors: Gómez, Sara, Gamazo, Carlos, Roman, Beatriz San, Ferrer, Marta, Sanz, Maria Luisa, Irache, Juan M
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 20-07-2007; Elsevier; Elsevier Limited
• Subjects: Adjuvants, Immunologic - administration & dosage; Administration, Oral; Allergens; Allergens - immunology; Allergies; Allergy and Immunology; Anaphylaxis - prevention & control; Animals; Antigens; Applied microbiology; Asthma; Biological and medical sciences; Brucella ovis; Brucella ovis - immunology; Cooling; Disease; Disease Models, Animal; Female; Fundamental and applied biological sciences. Psychology; Immunoglobulin G - blood; Immunotherapy; Immunotherapy - methods; Maleates - administration & dosage; Maleates - immunology; Mice; Mice, Inbred BALB C; Microbiology; Nanoparticles; Oral; Ovalbumin - immunology; Polysaccharides, Bacterial - immunology; Polyvinyls - administration & dosage; Proteins; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Spain; Nanoparticles; Immunotherapy; Oral; Immunopathology; Allergy; Immunological adjuvant; Allergen
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2007.05.020

Abstract The aim of this study was to investigate the adjuvant properties of oral-administered Gantrez® AN nanoparticles with ovalbumin (as allergen model) and, in some cases, lipopolysaccharide of Brucella ovis as immunomodulator. For this purpose, BALB/c mice were administered by oral gavage with OVA nanoparticles and both Th1 and Th2 markers (IgG2a and IgG1, respectively) were enhanced. On the other hand, these carriers administered by oral route were able to protect a model of sensitized mice to ovalbumin from anaphylactic shock. These results are highly suggestive for the valuable use of Gantrez® nanoparticles in oral immunotherapy with allergens.